GARDEN CITY, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today the establishment of an alliance with Duke University and Massachusetts General Hospital (MGH) to pursue advanced development and clinical studies of its lead therapeutics for treatment of ischemic stroke. An often debilitating if not fatal consequence of interrupted blood flow in the brain, ischemic stroke has long been deprived of effective treatments as a result of multiple clinical study failures over the past two decades. Angion Biomedica is pursuing novel therapeutic strategies targeting protective and regenerative systems in the brain using a small molecule mimetic of the growth factor called hepatocyte growth factor (HGF), and separately, a small molecule inhibitor of the poly(ADP-ribose) polymerase-1 (PARP-1) pathway.
